Introduction {#S1}
============

Personality disorders (PDs) are behavioral patterns with rigid traits that remain stable over time. The individual's developmental stage or social--cultural environment should not be used as an explanation of impairments in personality functioning and the individual's personality trait expression as it is explained in DSM-5. They directly affect perceptions, the way of thinking and relating to the world, and the control of individual impulses ([@B1]). Comorbidity of Axis I disorders complicates both the diagnosis and prognosis of PD ([@B2]). One of the most common comorbidities of patients with PD involves substance-use disorders (SUDs), and, *vice versa*, maladjustment ([@B3], [@B4]) and PD are more frequent among addicts ([@B5]--[@B7]).

Between 65 and 90% of individuals with addictions have PD ([@B8], [@B9]). The most commonly detected PD are Limit and Antisocial Cluster B ones; followed by Avoidant, Passive-aggressive and Obsessive--Compulsive PDs from Cluster C; and finally Schizotypal PD from Cluster A ([@B6], [@B10]). However, there are discrepancies, and not all studies coincide with this ranking. These discrepancies could be explained by the type of substance being consumed; the assessment methods or techniques used; the time of the assessment; being outpatients or inpatients; poly-consumption ([@B11], [@B12]), or even the stability of the disorders ([@B13]).

DSM-IV criteria seem to be a valid tool for the diagnosis of PD. A previous study supported the validity of the DSM-IV criteria for Avoidant PD in Hispanic population with SUDs ([@B14]).

Personality disorders from Cluster C (or core anxiety) group together excessively nervous or fearful individuals, who are characterized by great emotional instability that is evidenced by personal passivity and suffering. This cluster consists of Avoidant, Dependent, and Obsessive--Compulsive PDs ([@B1]). Cluster C traits could be detected even in adolescent population ([@B15]). Adolescents with maladaptative personality traits are more at risk of developing cannabis dependence or other SUDs ([@B16]).

To explain the association between PD Cluster C and SUD, two hypotheses have been put forward. One is the self-medication hypothesis, which proposes that individuals discover that substances alleviate or change a series of painful affective states ([@B17], [@B18]). In the specific case of Cluster C, directly linked to anxiety, it is hypothesized that consumption of substances is aimed at counteracting feelings of isolation and a lack of social relations. Consequently, drugs can be used to substitute these relations or simply produce a feeling of tranquility in social situations. These characteristics indicate a tendency among patients in this group of disorders toward an overall greater drug consumption, including alcohol and other substances, both stimulants and depressants ([@B19], [@B20]).

The second hypothesis, known as *stress response dampening*, suggests that individuals with high scores in personality traits like stress reactivity, sensitivity to anxiety, and neuroticism are vulnerable to stressful events. These individuals tend to respond to stress with anxiety and mood swings, which can, in turn, push them toward substance consumption ([@B2]).

Beyond these hypotheses, previous studies have shown anatomo-functional correlates between Cluster C addicted patients and their willingness to change ([@B21]).

Furthermore, it has been suggested that patients with SUD who have PD usually show more psychopathological problems, mainly anxiety and depression ([@B8], [@B22]--[@B25]). Kranzler et al. ([@B26]) highlight that anxiety and depression are substantially higher among SUD patients with PDs than among those without. Additionally, Langås et al. point out that symptoms of depression and addiction are more serious in SUD patients with PD ([@B8]). Despite studies on the existence of psychiatric comorbidity between Cluster C and SUD ([@B8], [@B20]) and of the possible influence of anxiety and depression on PD, there have been no studies involving large samples on the influence of anxiety and depression on patients with Cluster C PD.

Therefore, the aim of this work is to determine the prevalence of Cluster C PD in patients with SUD who seek treatment, to analyze differences in clinical variables between the various disorder subtypes of Cluster C and evaluate if the variables of anxiety and depression differentiate these patients from those who do not present disorders of this cluster. We hypothesize that Cluster C disorders will be common in addicts, that there will be clinical and consumption differences among the different disorders of this cluster, and that anxiety and depression will be distinct in each disorder and will influence clinical variables differently.

Materials and Methods {#S2}
=====================

Participants {#S2-1}
------------

This descriptive study involved a clinical sample of 822 substance dependent patients according to the DSM-IV-TR criteria (621 males and 201 females, mean age = 38.35, SD = 10.14, range 18--78). The study was conducted in the outpatient drug clinic of Vall d'Hebron Hospital's Psychiatry Service of the (CAS Vall d'Hebron) in Barcelona, Spain.

Measures {#S2-2}
--------

Patients were visited by a psychiatrist, and three psychological evaluation visits were carried out by psychologists. The psychological evaluation visits were carried out in the first month of starting treatment in our Unit. Sociodemographic and clinical data were recorded using a questionnaire designed *ad hoc*, as well as evaluating all patients using the following instruments.

SCID I (The Structured Clinical Interview for DSM-IV Axis I disorders), a widely used scale that has shown good psychometric properties, was used to assess SUD ([@B27]).

SCID II (The Structured Clinical Interview for DSM-IV for Axis II) was used to assess PDs. This tool has shown adequate reliability and usefulness providing clear discrimination among Axis II disorders ([@B28]).

Beck Depression Inventory (BDI) ([@B29], [@B30]) is scored by summing the rating for all its 21 items to obtain a total score ranging from 0 to 63. Each symptom's severity is rated on a 4-point scale (0--3).

State-Trait Anxiety Inventory (STAI) ([@B31]) is a 40-item measure that indicates the intensity of feelings of anxiety. It distinguishes between state anxiety (i.e., a temporary condition experienced in specific situations) and trait anxiety (i.e., a general tendency to perceive situations as threatening). Each scale consists of 20 items rated on a 4-point Likert scale. STAI has demonstrated good internal consistency, test--retest reliability in trait anxiety, sensitivity to detection of stress in state anxiety, and convergent and discriminant validity ([@B32]--[@B35]).

Procedure {#S2-3}
---------

Data were collected between January 2005 and June 2013. Inclusion criteria were patients were 18 years or older, presented substance dependence according to DSM-IV-TR, provided a signed consent form to participate in the study, and finished the assessment process. Exclusion criteria were: intoxication at baseline examination, severe somatic disease at baseline examination, and low language proficiency. The study protocol was approved by the hospital's ethics committee (Comité Ético de Investigación Clínica Vall d'Hebron). Patients did not receive monetary compensation for their participation in the study. This study was part of a wider project on comorbidity on drug dependence.

Using IBM SPSS 19, cross-tabs with χ^2^, differential analysis with Student's *t* and Cohen's *d*, and Pearson's *r* were performed. To study poly-consumption, regardless of the main drug being treated, data were crossed on different substance use and the variable PD criteria. To facilitate calculations, each use/or abuse variable is dichotomized in such a way that no-use is scored with a 0 and the use-abuse-dependence is 1.

Results {#S3}
=======

Demographics and Comorbidity PD-SUD {#S3-1}
-----------------------------------

In the sample, 9.5% of patients fulfilled the criteria for at least one PD from Cluster C, with the most frequent diagnosis being Avoidant PD. In addition, 28.9% fulfilled PD criteria for Clusters A and B but not for C, and 61.6% did not fulfill the criteria for any PD (see Table [1](#T1){ref-type="table"}).

###### 

Social, demographical, and clinical characteristics.

  ----------------------------------- --------- -------------------------- -------------------------- ---------------------------------- ---------------------- --------------- --------------- --------- ------- --------- ------- --------- ------- --------- ------- --------- -------
                                                                                                      **Without personality disorder**   **Clusters A and B**   **Cluster C**   **Cluster C**                                                                                     
                                                **Total**                  **Avoidant**               **Depend**                         **Obs--comp**          **Comorb.**                                                                                                       
                                                                                                                                                                                                                                                                                  
                                                ***n***                    **%**                      ***n***                            **%**                  ***n***         **%**           ***n***   **%**   ***N***   **%**   ***n***   **%**   ***n***   **%**   ***n***   **%**
                                                                                                                                                                                                                                                                                  
                                                822                        100                        506                                61.8                   238             28.9            78        9.5     35        44.9    9         11.5    29        37.2    5         6.4
                                                                                                                                                                                                                                                                                  
  Sex                                 Males     621                        75.5                       388                                76.7                   178             74.8            55        70.5    24        68.6    3         33.3    24        85.7    4         75.7
  Females                             201       24.5                       118                        23.3                               60                     25.2            23              29.5      11      31.4      6       66.7      5       14.3      1       24.3      
                                                                                                                                                                                                                                                                                  
  Age                                 Mean      38.35                      39.85                      35.29                              37.69                  37.91           36.33           38.21     35.6                                                                    
  SD                                  10.12     10.61                      8.50                       9.07                               10.15                  11.97           9.44            3.78                                                                              
  Range                               18--78    18--78                     18--69                     18--60                             18--57                 21--60          22--58          32--41                                                                            
                                                                                                                                                                                                                                                                                  
                                                *F* = 17.11, *p* = 0.000   *F* = 0.339, *p* = 0.797                                                                                                                                                                               
                                                                                                                                                                                                                                                                                  
  Substance-use disorders-treatment   Alcohol   233                        100                        177                                76.0                   34              14.6            22        9.4     10        45.4    1         4.5     11        50.0    0         0.0
  Benzodiazepines                     27        100                        19                         70.3                               3                      11.1            5               18.5      2       40.0      2       40.0      1       20.0      0       0.0       
  Opioids                             147       100                        75                         51.0                               63                     42.9            9               6.1       4       44.4      0       0.0       4       44.4      1       11.1      
  Amphetamines                        7         100                        4                          57.1                               3                      42.9            0               0.0       0       0.0       0       0.0       0       0.0       0       0.0       
  Cocaine                             319       100                        185                        58.0                               103                    32.3            31              9.7       13      41.9      5       16.1      10      32.3      3       9.7       
  Cannabis                            89        100                        46                         51.7                               32                     36.0            11              12.3      6       54.5      1       9.1       3       27.3      1       9.1       
  ----------------------------------- --------- -------------------------- -------------------------- ---------------------------------- ---------------------- --------------- --------------- --------- ------- --------- ------- --------- ------- --------- ------- --------- -------

Patients with a Cluster C disorder often had another PD: 14 Avoidant PD, 4 Dependent PD, and 5 Obsessive--Compulsive PD and also met the criteria for one or more PD from Clusters A and B (17.9, 5.12, and 6.4%, respectively within Cluster C). Finally, 5 (6.4%) participants showed two or three PD from Cluster C together with one or more PD from Clusters A and B.

It was found that 70.5% of patients with a Cluster C PD were men, although there were clear differences in the type of PD, Obsessive--Compulsive PD (85.7%) was the most common and to a significantly lesser degree Dependent PD (33.7%) (χ^2^ = 12.19, *p* = 0.007).

The average age of patients was over 35 years old with statistically significant differences between the Without PD group and the group of patients from Clusters A and B (39.85 and 35.29, respectively, *t* = 6.28, *p* \< 0.001). Within Cluster C, there were no differences in age (*F* = 0.339, *p* = 0.797).

A different pattern in PD prevalence was identified depending on the main substance consumed. Thus, Dependent PD was mainly present in patients who consumed benzodiazepines, and Obsessive--Compulsive PD were more common among those who consumed alcohol, opioids, cocaine, and cannabis.

Poly-Consumption of Drugs Regardless of Substance Use of Treatment {#S3-2}
------------------------------------------------------------------

Table [2](#T2){ref-type="table"} shows the data for use/abuse of substances depending on their main effect on central nervous system (depressants, stimulants, and hallucinogens).

###### 

Drug abuse of among drug-dependent patients.

  ------------------------- -------------------------------------------------- -------------------------------------- ------------------------------ ------- --------- ----------------------------- ----------------------------- -------------------------------- --------------------------- ------- --------- ------- --------- ------- --------- ------- ---------- ---------
                                                                                                                      **Cluster C**                                                                                                                                                                                                                                      
                            **Without personality disorder (***n*** = 506)**   **Clusters A and B (***n*** = 238)**   **Cluster C (***n*** = 78)**                     **Avoidant (***n*** = 35)**   **Dependent (***n*** = 9)**   **Obsess--com (***n*** = 29)**   **Comorb. (***n*** = 5)**                                                                            
                            ***n***                                            **%**                                  ***n***                        **%**   ***n***   **%**                         **χ^2^**                      ***p***                          ***n***                     **%**   ***n***   **%**   ***n***   **%**   ***n***   **%**   **χ^2^**   ***p***
                                                                                                                                                                                                                                                                                                                                                                         
  **Depressant drugs**                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                         
  Alcohol                   431                                                85.2                                   190                            79.8    57        74.0                          7.88                          0.02                             25                          71.4    6         66.7    23        82.1    3         60.0    1.45       0.627
   *Only alcohol*           15                                                 2.96                                   --                             --      --        --                            --                            --                               3                           8.6     --        --      --        --      --        --      --         --
  Benzodiazepine            159                                                31.4                                   102                            42.9    30        39.0                          9.59                          0.008                            13                          37.1    3         33.3    12        42.9    2         40.0    0.42       0.935
   *Only benzodiazepines*   1                                                  0.20                                   --                             --      --        --                            --                            --                               1                           2.9     1         11.1    --        --      --        --      --         --
  Opioid                    119                                                23.5                                   91                             38.2    18        23.4                          18.2                          0.0001                           10                          28.6    3         33.3    4         14.3    1         20.0    2.47       0.481
  Methadone                 103                                                20.4                                   78                             32.8    15        23.4                          11.0                          0.004                            8                           27.4    2         28.4    4         16.4    1         25.0    1.31       0.728
                                                                                                                                                                                                                                                                                                                                                                         
  **Stimulant drugs**                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                         
  Amphetamines              92                                                 18.2                                   59                             24.8    20        26.0                          5.58                          0.06                             6                           17.7    2         22.2    11        39.3    1         20.0    4.85       0.183
  Cocaine                   336                                                66.4                                   203                            85.3    51        66.2                          29.6                          0.0001                           21                          60.0    7         77.8    19        67.9    4         80.0    2.33       0.507
   *Only cocaine*           2                                                  0.40                                   --                             --      --        --                            --                            --                               2                           5.7     1         11.1    --        --      --        --      --         --
  Tobacco                   405                                                80.0                                   197                            82.8    45        66.2                          21.8                          0.0001                           20                          64.5    5         62.5    18        75.0    2         40.0    1.45       0.693
                                                                                                                                                                                                                                                                                                                                                                         
  **Hallucinogen drugs**                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                         
  Ecstasy                   99                                                 19.6                                   59                             24.8    12        19.4                          2.61                          0.271                            2                           10.3    1         16.7    8         34.8    0         0.0     6.21       0.102
  Cannabis                  289                                                57.1                                   167                            70.2    45        58.4                          11.6                          0.003                            17                          48.6    6         66.7    18        64.3    4         80.0    4.41       0.221
   *Only cannabis*          --                                                 --                                     1                              0.42    --        --                            --                            --                               --                          --      1         11.1    --        --      --        --      --         --
  ------------------------- -------------------------------------------------- -------------------------------------- ------------------------------ ------- --------- ----------------------------- ----------------------------- -------------------------------- --------------------------- ------- --------- ------- --------- ------- --------- ------- ---------- ---------

Alcohol, tobacco, cocaine, and cannabis were the drugs consumed by the majority of patients. However, patients without PD---compared to those with---showed greater alcohol consumption (χ^2^ = 7.88, *p* = 0.02). Compared to patients with disorders from Cluster A and B, those with Cluster C disorders and those without PD consumed fewer opiates (χ^2^ = 18.2, *p* = 0.000) and less methadone (χ^2^ = 11.0, *p* = 0.004). There was a higher percentage of patients with PD that consumed benzodiazepines (χ^2^ = 9.59, *p* = 0.008) compared to those patients without PD.

In the case of stimulants, patients with Cluster C PD typically showed lower tobacco consumption (χ^2^ = 21.8, *p* \< 0.0001), whereas cocaine was used by patients from Clusters A and B (χ^2^ = 29.6, *p* \< 0.0001), there were no differences among amphetamine use.

Finally, regarding drugs with hallucinogenic effects, there were no differences in the use of ecstasy, but there were for cannabis with patients with Cluster C PD and those Without PD being the ones that consume the least (χ^2^ = 11.6, *p* = 0.003).

Within Cluster C, there were no statistically significant differences though there was a higher percentage of Obsessive--Compulsive PD who consumed alcohol, benzodiazepines, amphetamines, and tobacco compared with the other two PD from Cluster C.

In the sample, 96.6% of patients were poly-consumers with the exception being the Avoidant PD of whom 80% were poly-consumers (28 participants).

There were 15 patients Without PD and 3 Avoidant PD who only consumed alcohol; there was 1 Without PD, 1 Avoidant PD, and 1 Dependent PD only using benzodiazepines; those only on cocaine were 2 Without PD, 2 Avoidant PD, and 1 Dependent PD; and those only on cannabis were 1 Avoidant PD and 1 Cluster A and B PD. In other words, poly-consumption is almost universal in SUD.

Depressive Symptomatology and Anxiety {#S3-3}
-------------------------------------

The levels of depression and trait anxiety and state anxiety were studied as a function of Axis II (Figure [1](#F1){ref-type="fig"}). Significant differences appeared among different clusters and *post hoc* comparisons demonstrated that participants with Cluster C had more depressive symptoms (*F* = 28.63, *p* \< 0.001) and greater state anxiety (*F* = 30.60, *p* \< 0.001) than those with Cluster A and B PD, and those participants Without PD. However, trait anxiety (*F* = 13.39, *p* \< 0.001) was similar for PD within Axis II and higher for participants Without PD.

![Anxiety and depression according to the instrument of evaluation.](fpsyt-09-00019-g001){#F1}

Having performed comparisons within Cluster C and owing to the size of the sample, it was decided to calculate the size of Cohen's *d* effect (Table [3](#T3){ref-type="table"}). Depressive symptomatology, as measured by BDI, was similar for Avoidant PD and Dependent PD (Cohen's *d* close to 0), whereas the Obsessive--Compulsive PD scored higher (large Cohen's *d*).

###### 

Anxiety and depression within Cluster C.

           Avoidant   Dependent   Obsessive--compulsive   Cohen's *d*                                                                                                   
  -------- ---------- ----------- ----------------------- ------------- ------ ------- ---------------------------------------- --------------------------------------- ---------------------------------------
  BDI      26.3       12.2        27.7                    13.7          19.6   9.9     −0.11[^a^](#tfn1){ref-type="table-fn"}   0.61[^c^](#tfn3){ref-type="table-fn"}   0.69[^c^](#tfn3){ref-type="table-fn"}
  STAI-T   39.4       11.2        48.1                    21.2          35.4   12.2    −0.54[^c^](#tfn3){ref-type="table-fn"}   0.34[^b^](#tfn2){ref-type="table-fn"}   0.76[^c^](#tfn3){ref-type="table-fn"}
  STAI-S   34.3       12.9        41.4                    21.2          31.3   14.27   −0.42[^b^](#tfn2){ref-type="table-fn"}   0.22[^b^](#tfn2){ref-type="table-fn"}   0.57[^c^](#tfn3){ref-type="table-fn"}

*^a^Close to 0 *d* (*d* ≤ 0.19)*.

*^b^Moderate *d* (0.20 ≤ *d* ≤ 0.50)*.

*^c^Large *d* (*d* \> 0.50)*.

*BDI, Beck Depression Inventory; STAI-T and STAI-S, State-Trait Anxiety Inventory*.

Additionally, regarding anxiety there were clear differences within Cluster C: Dependent PD scored higher than Avoidant and Obsessive--Compulsive PD (Cohen's *d* moderate and large in both comparisons). Those with Avoidant PD scored higher than Obsessive--Compulsive, although the difference was more moderate.

Furthermore, depressive symptomatology and anxiety were significantly positively correlated (Table [4](#T4){ref-type="table"}). However, when PD types within Cluster C were analyzed, anxiety was not related to the depressive symptomatology in Dependent PD (*r* = −0.05 and *r* = 0.10 for trait and state anxiety, respectively).

###### 

Relationships among depression and anxiety.

  -------- ------------------------------ ------------------ ------------ ------------ ------------ ------------------ ---------------------------------------- ------------ -------- ------------ ------------ ------------ -------- --------
                                                                                                                       Cluster C                                                                                                      
           Without personality disorder   Clusters A and B   Cluster C    Avoidant     Dependent    Obsessive--comp.   Comorb.                                                                                                        
           STAI-T                         STAI-S             STAI-T       STAI-S       STAI-T       STAI-S             STAI-T                                   STAI-S       STAI-T   STAI-S       STAI-T       STAI-S       STAI-T   STAI-S
                                                                                                                                                                                                                                      
  BDI      0.66\*\*\*                     0.62\*\*\*         0.63\*\*\*   0.61\*\*\*   0.53\*\*\*   0.63\*\*\*         0.54[\*\*](#tfn4){ref-type="table-fn"}   0.80\*\*\*   -0.05    0.10         0.82\*\*\*   0.76\*\*\*   0.96     0.49
  STAI-T                                  0.69\*\*\*                      0.67\*\*\*                0.77\*\*\*                                                  0.70\*\*\*            0.95\*\*\*                0.77\*\*\*            0.49
  -------- ------------------------------ ------------------ ------------ ------------ ------------ ------------------ ---------------------------------------- ------------ -------- ------------ ------------ ------------ -------- --------

*\*\* p ≤ 0.01, \*\*\* p ≤ 0.001*.

*STAI-T and STAI-S, State-Trait Anxiety Inventory; BDI, Beck Depression Inventory*.

Regardless of having a PD or not, there was a close relationship between depression and anxiety, but it was found that within Cluster C, patients with Dependent PD were different to the rest as their responses did not indicate any relation between depression and anxiety.

Depressive Symptomatology and Anxiety in Relation to Treatment Indicators {#S3-4}
-------------------------------------------------------------------------

To analyze the relevance of depressive symptomatology and anxiety with objective indicators of treatment, the corresponding correlations between depression, trait anxiety, and state anxiety scales were calculated for three treatment indicators: number of detoxifications, number of admissions and number of treatments in health centers.

In participants Without PD and in participants with Cluster A and B PD, the range of *r* was −0.7 and 0.13, indicating the absence of a relation between psychological factors and treatment indicators. However, for Cluster C, though the general scenario is similar to the one above, correlations of 0.24 appear between the two scales of anxiety and depression. Carrying out a zonal analysis within this cluster (Table [5](#T5){ref-type="table"}), in the case of Avoidant PD and Obsessive--Compulsive PD, the correlation pattern approaches 0. However, in Dependent PD, there are high negative correlations between depressive symptomatology and treatment indicators, whereas there are moderately positive ones between trait and state anxiety and the indicators, except for the number of detoxifications. When cases of comorbidity within Cluster C were analyzed, the scenario was different: state anxiety was lower, the greater the number of detoxifications and treatments, while the number of admissions increased with greater depressive symptomatology and greater trait anxiety.

###### 

Relationships among depression/anxiety and treatment keys in Cluster C.

                  Avoidant   Dependent   Obsessive--compulsive   Comorb.                                                                         
  --------------- ---------- ----------- ----------------------- ------------- ---------- ---------- ------ ------ ------- ---------- ---------- -----------
                                                                                                                                                 
  Detox           0.06       −0.10       0.03                    **−0.64**     0.19       0.00       0.16   0.07   0.18    **0.37**   **0.39**   **−0.50**
  Ingress         0.07       0.04        −0.06                   −**0.62**     **0.65**   **0.50**   0.10   0.10   0.24    --         --         --
  Outpatient T.   −0.07      0.06        v0.09                   **−0.94\***   **0.48**   **0.36**   0.06   0.10   −0.02   −0.10      0.02       **−0.49**

*Detox, number of inpatient detoxification; Ingress, number of ingress in Therapeutical Community; Outpatient T, outpatient treatment, number of outpatient treatment performed before; STAI-T and STAI-S, State-Trait Anxiety Inventory; BDI, Beck Depression Inventory*.

*Correlations with absolute values of 0.30 or above are given in bold type (\**p* ≤ 0.05)*.

Discussion {#S4}
==========

Almost 40% of the patients studied have a PD and nearly 10% have a PD from Cluster C. The findings obtained in seeking treatment patients attended at outpatient clinical units is consistent with other studies with smaller samples ([@B8], [@B9], [@B20], [@B36]) and manly carried out in inpatient units ([@B4], [@B7], [@B10], [@B13]) or only taking into account one specific substance ([@B12]).

It is possible that a large number of results from studies on comorbidity in SUD could be attributed to the characteristics of the personality pathologies, themselves ([@B37]). However, it has also been postulated that some interactions between drugs, like alcohol and nicotine ([@B38]) or psychoactive substances used simultaneously, like cocaine and alcohol ([@B39]), could explain a certain degree of comorbidity.

The general trend in clinical practice seems to identify anxiety and depression mainly in Cluster B patients and *vice versa* because they seem to present themselves and their symptoms in a more "visible" way. Based on the results of this study it seems to be advisable to identify Cluster C patients in the Addiction Treatment Centers and take into account the fact that this population has high rates of anxiety and depression symptoms.

It is worth noting that patients with Cluster C disorders present maladjustment traits often characterized by high levels of anxiety. Based on the theory of self-medication, SUD could have developed or have been maintained in order to mitigate the consequences of these personality traits. Thus, dealing with these traits and symptoms could be of great interest. Moreover, chronic substance dependence can lead to affective dysregulation, which can contribute to the personality pathology ([@B40]). There are new evidence regarding changes in neurobiology and behavior following intermittent ethanol consumption, leading to increase in social anxiety, altered synapses, and reduced neurogenesis, cholinergic, and serotonergic neurons ([@B41]).

In Cluster C, PD the most commonly substances for consulting are benzodiazepines. These findings could be explained by the anxiolytic effect of these drugs. On the other hand, patients with PD from this cluster frequently show alcohol dependence (74%). These results support the observed tendency in patients from this group of disorders toward greater alcohol consumption as well as abuse of both stimulants and depressants, which coincides with previous studies ([@B19], [@B20], [@B42]--[@B45]). The prevalence of dependence in legal drugs (alcohol and benzodiazepines) is similar to the other PD group. In contrast, the prevalence of dependence to illegal drugs (opiates, cocaine, and cannabis) is similar to the patients without a PD. It could be hypothesized that they are avoiding the illegal circuits because of obsessive and avoiding cognitions/behaviors and the high levels of stress.

Regardless of the main substance of abuse, poly-consumption is the norm in all patients, though to a lesser extent for those with Avoidant PD. This fact highlights a disturbing situation in which it is necessary to clarify the implications of each substance and their interaction when inside the body. Poly-consumption is an extremely risky practice and requires the assessment of each individual's particular circumstances to design an appropriate intervention program for that individual's needs.

The prevalence of men in Cluster C PD is higher, except in the Dependent group, and as opposed to other disorders, there is no correlation between anxiety and depression.

Psychological functioning related to depression and anxiety is characteristic of Cluster C. In fact, the data in this study confirm that patients from Cluster C score higher than other patients (both Without PD and Cluster A and B groups) in depression and state anxiety. However, in their trait anxiety, there are no differences with other PD patients, though they do score higher than patients Without PD. Specifically, within Cluster C, Obsessive--Compulsive PD patients present fewer depressive symptoms and less anxiety (trait and state) than Avoidant and Dependent PD. Therefore, the results on anxiety and depression do not show just one pattern for all the patients with SUD-PD. It is worth highlighting that, as observed in previous studies ([@B46], [@B47]), patients with Cluster C PD are most commonly affected by depression; however, they are not the group with greatest trait anxiety.

Nevertheless, it cannot be ignored that among patients with mood disorders or anxiety, Obsessive--Compulsive, and Avoidant disorders from Cluster C are the most frequent and have the worst prognosis ([@B48], [@B49]). Moreover, the close relation between anxiety and depression for all the groups except for the Dependent PD group clearly shows the complexity of the relation and suggests that in many patients intervention should focus on aspects like depression and anxiety more than on the substance being consumed.

Furthermore, it is important to underline the singularity of the Dependent PD group. For these patients, the negative relation between depression and treatment indicators and positive relation between anxiety and treatment indicators clearly shows that this group within Cluster C should be treated as a distinct group with specific features that need to be considered at treatment level.

This is the first description of the relationship between Cluster C PD and SUD in a clinically large sample. One of the strong points of this study is the use of a systematic evaluation process using semi-structured interviews that provide high diagnostic reliability. As we noted before, the size of most samples studied about these topic have been smaller in comparison to the number of participants included in this research.

The results of the present study should be interpreted in light of the following limitations. The results are limited to patients with PD seeking treatment in a drug unit. It would be very interesting to confirm if SUD patients treated in residential centers show the same prevalence of Cluster C PD; if depression and anxiety are also differential psychological indicators within this Cluster; and if there is the same relation with treatment indicators in a residential center. On the other hand, it seems of interest studying other possible variables such as other comorbidities, the age of onset, family history, and so on.

Finally, it is necessary to analyze the possible implications of basic temperamental traits both in the description of SUD---Cluster C patients as well as in the differential treatment of their addiction.

Reciprocal relationship between substance use, mood, and anxiety disorders has been found ([@B49]--[@B51]). Given the prevalence of Cluster C disorders in addicts, their systematic assessment should be implemented for all patients seeking treatment. The presence of depression symptoms and anxiety traits can be useful to detect the most serious patients and with whom a specific approach should be adopted, especially in Dependent PD.
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